Last reviewed · How we verify
paclitaxel liposome injection plus cisplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
paclitaxel liposome injection plus cisplatin (paclitaxel liposome injection plus cisplatin) — Nanjing Luye Sike Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| paclitaxel liposome injection plus cisplatin TARGET | paclitaxel liposome injection plus cisplatin | Nanjing Luye Sike Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- paclitaxel liposome injection plus cisplatin CI watch — RSS
- paclitaxel liposome injection plus cisplatin CI watch — Atom
- paclitaxel liposome injection plus cisplatin CI watch — JSON
- paclitaxel liposome injection plus cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). paclitaxel liposome injection plus cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-liposome-injection-plus-cisplatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab